Table 2 Subject demographics and characteristics at conversion to darbepoetin alfa Q2W
From: Extended dosing of darbepoetin alfa in peritoneal dialysis patients
n = 741 | |
|---|---|
Sex, n (%) | |
Female | 318 (42.9) |
Male | 421 (56.8) |
Not recorded | 2 (0.3) |
Age (years), mean (SD) | 61.2 (15.2) |
Age (years), n (%) | |
<65 | 413 (55.7) |
≥65 | 328 (44.3) |
Primary cause of CKD, n (%) | |
Diabetes mellitus | 140 (18.9) |
Glomerulonephritis | 139 (18.8) |
Hypertension | 137 (18.5) |
Unknown etiology | 108 (14.6) |
Polycystic kidney/hereditary disease | 67 (9.0) |
Interstitial nephropathy/obstructive nephropathy | 63 (8.5) |
Tumors | 6 (0.8) |
Other | 81 (10.9) |
Duration of dialysis (years), mean (SD) | 3.1 (3.6) |
Duration of dialysis (years), n (%) | |
<2 years | 231 (31.2) |
2-5 years | 429 (57.9) |
>5 years | 81 (10.9) |
History of cardiovascular disease, n (%) | 379 (51.1) |
History of diabetes, n (%) | 210 (28.3) |
Type 1 | 30 (4.0) |
Type 2 | 173 (23.3) |
Diabetic, type not recorded | 7 (0.9) |
Duration of ESA usea (years), mean (SD) | 2.8 (2.0) |
Hb concentration at conversion, g/dL, n (%) | |
≤11 | 167 (22.5) |
>11-13 | 307 (41.4) |
>13 | 228 (30.8) |
Not recorded | 39 (5.3) |
ESA treatment prior to conversion, n (%) | |
Darbepoetin alfa | 564 (76.1) |
Epoetin alfa | 19 (2.6) |
Epoetin beta | 92 (12.4) |
ESA naïveb | 66 (8.9) |
ESA frequency prior to conversionc, n (%) | |
TIW or BIW | 20 (3.0) |
QW | 529 (78.4) |
Other | 124 (18.4) |
Not recorded | 2 (0.3) |
ESA route prior to conversionc, n (%) | |
IV | 41 (6.1) |
SC | 634 (93.9) |
Darbepoetin alfa route at conversion, n (%) | |
IV | 24 (3.2) |
SC | 717 (96.8) |
Darbepoetin alfa weekly dose at conversion, μg/wk | |
Geometric mean (95% CI) | 18.89 (18.13-19.68) |
Iron status, n (%) | |
Serum ferritin >100 μg/L and either TSAT >20% or hypochromic red cells <10% | 255 (34.4) |
Serum ferritin ≤100 μg/L or both TSAT ≤20% and hypochromic red cells ≥10% | 161 (21.7) |
Not recorded | 325 (43.9) |